Page 47 - 《中国药房》2025年12期
P. 47

载雷公藤甲素靶向制剂的制备及质量、靶向性、细胞毒性评价
                                                                                                       Δ


                                                                    1 #
                                                   3
                                   1
                          1
                                                           1
          尹茉莉 ,罗文彬 ,徐婧哲 ,唐泽波 ,郭 妮 ,劳友幸 ,王会岩 (1.吉林医药学院吉林省抗体工程科技协同
                 1*
                                           2
          创新中心,吉林 吉林 132013;2.吉林医药学院基础医学院,吉林 吉林 132013;3.西安交通大学第二附属
          医院生物诊疗中心,西安 710299)
          中图分类号  R944;R965      文献标志码  A      文章编号  1001-0408(2025)12-1457-06
          DOI  10.6039/j.issn.1001-0408.2025.12.07
          摘  要  目的  制备雷公藤甲素(TP)纳米粒子靶向制剂,并评价其质量、靶向性和细胞毒性作用。方法  使用乳化挥发法,以聚乳
          酸-羟基乙酸共聚物/聚乙二醇/叶酸(PLGA-PEG-FA)为载体,制备载TP靶向FA受体的聚合物纳米粒子(TP@PLGA-PEG-FA),观
          察其形态及分布,测定其粒径、Zeta 电位、多分散性指数(PDI)、载药量、包封率,评价其稳定性、血液相容性、体外释药情况、
          RAW264.7细胞摄取情况(以荧光染料Cy3.5定位)和体外细胞毒性。结果  TP@PLGA-PEG-FA呈球形,分布均匀,粒径为(122.60±
          0.02)nm,Zeta 电位为(-17.6±0.6)mV,PDI 为 0.26±0.02;TP 的载药量和包封率分别为(7.78±0.05)%和(68.62±0.03)%;其在
          4 ℃水中放置 14 d 和在 37 ℃、含有 10% 胎牛血清的 DMEM 培养基中放置 12 h 的粒径、PDI、Zeta 电位均无明显变化。100、200、
          300、400 µg/mL TP@PLGA-PEG-FA的溶血率分别为0.77%、0.92%、1.34%、1.63%。TP@PLGA-PEG-FA在pH5.5的磷酸盐缓冲液
          中72 h时的累积释放量为(84.83±0.29)%,较pH7.4、6.5磷酸盐缓冲液中72 h时的累积释放量[分别为(42.37±0.35)%、(63.83±
          0.29)%]显著升高(P<0.05)。激活的RAW264.7细胞对Cy3.5@PLGA-PEG-FA的摄取明显多于其对Cy3.5@PLGA-PEG-FA+游离
          FA和Cy3.5@PLGA-PEG的摄取;当TP质量浓度≥15.63 ng/mL时,TP@PLGA-PEG-FA组激活细胞的存活率显著低于同质量浓度
          游离TP组(P<0.05)。结论  所制备的TP@PLGA-PEG-FA稳定性高、血液相容性好,对炎症细胞具有主动靶向性和细胞毒性。
          关键词  雷公藤甲素;类风湿关节炎;细胞毒性;靶向制剂;纳米粒子


          Preparation and evaluation of quality, targeting and cytotoxicity of triptolide-loaded targeting nanoparticles
                                                                     3
                                                                                    1
                                                           2
                                 1
                                                                                                    1
          YIN Moli ,LUO Wenbin ,XU Jingzhe ,TANG Zebo ,GUO Ni ,LAO Youxing ,WANG Huiyan (1.  Jilin
                                              1
                   1
          Collaborative  Innovation  Center  for Antibody  Engineering,  Jilin  Medical  University,  Jilin  Jilin  132013,  China;
          2.  College  of  Basic  Medicine,  Jilin  Medical  University,  Jilin  Jilin  132013,  China;3.  National-Local  Joint
          Engineering Research Center of Biodiagnostics and Biotherapy, the Second Affiliated Hospital of Xi’an Jiaotong
          University, Xi’an 710299, China)
          ABSTRACT   OBJECTIVE  To  prepare  nanoparticle-based  targeting  preparation  loaded  with  triptolide (TP),  and  evaluate  its
          quality,  targeting  ability  and  cytotoxic  effects.  METHODS  Polymer  nanoparticles  carrying  TP-targeted  folic  acid (FA)  receptor
         (TP@PLGA-PEG-FA)  were  fabricated  using  poly (lactic-co-glycolic  acid)/polyethylene  glycol/FA (PLGA-PEG-FA)  as  the  carrier
          by  emulsion  and  volatilization  technique.  The  morphology  and  distribution  were  observed,  and  their  particle  size,  Zeta  potential,
          polydispersity index (PDI), drug loading capacity and encapsulation efficiency were measured. Their stability, blood compatibility,
          in  vitro  drug  release,  uptake  by  RAW264.7  cells (localization  with  fluorescent  dye  Cy3.5),  and  in  vitro  cytotoxicity  were
          evaluated. RESULTS TP@PLGA-PEG-FA exhibited spherical shape and uniform distribution, with particle size of (122.60±0.02)
          nm,  Zeta  potential  of (-17.6±0.6)mV,  and  PDI  of  0.26±0.02;  drug  loading  capacity  and  encapsulation  efficiency  of  TP  were
          measured to be (7.78±0.05)% and (68.62±0.03)%, respectively. The hemolysis rates of 100, 200, 300, 400 µg/mL TP@PLGA-
          PEG-FA  were  0.77%,  0.92%,  1.34%  and  1.63%,  respectively.  There  were  no  significant  changes  in  particle  size,  PDI  and  Zeta
          potential  when  TP@PLGA-PEG-FA  were  placed  in  4  ℃  water  for  14  days  and  in  DMEM  culture  medium  containing  10%  fetal
                                                             bovine serum at 37 ℃ for 12 h. The cumulative release rate of
             Δ 基金项目 吉 林 省 科 技 发 展 计 划 项 目(No. YDZJ20240203-
                                                             TP@PLGA-PEG-FA  was (84.83±0.29)%  in  phosphate  buffer
          0CXJD,No. YDZJ202101ZYTS095);吉 林 省 中 医 药 科 技 项 目(No.
          2024161);吉林省大学生创新创业训练计划项目(No.S202313706005,        at  pH5.5  for  72  h,  which  was  significantly  higher  than  the
          No.S202413706028)                                  cumulative  release  rates  in  phosphate  buffer  solutions  at  pH7.4
             *第一作者 实验师,博士。研究方向:药物新剂型。E-mail:
                                                             and  6.5  for  72  h  [(42.37±0.35)%  and (63.83±0.29)% ,
          80630963@qq.com
             #  通信作者 教 授 ,博 士 。 研 究 方 向 :药 物 新 剂 型 。 E-mail:  respectively] (P<0.05).  Activated  RAW264.7  cells  took  up
          zswhy518@163.com                                   significantly  more  Cy3.5@PLGA-PEG-FA  than  they  took  up


          中国药房  2025年第36卷第12期                                              China Pharmacy  2025 Vol. 36  No. 12    · 1457 ·
   42   43   44   45   46   47   48   49   50   51   52